16results about "Disrupted materials" patented technology

Disclosed are methods of delivering a therapeutic to a target site of a subject comprising administering a lipid capsule to a target site of a subject, wherein the lipid capsule comprises a therapeutic agent; and applying an alternating electric field, at a frequency for a period of time, to the target site of the subject, wherein the alternating electric field releases the therapeutic from lipid capsule at the target site of the subject. Disclosed are methods of increasing target site specific release of a therapeutic agent in a subject comprising administering a lipid capsule to a target site of a subject, wherein the lipid capsule comprises a therapeutic agent; and applying an alternating electric field, at a frequency for a period of time, to the target site of the subject, wherein the alternating electric field releases the therapeutic agent from the lipid capsule at the target site of the subject, thereby increasing the target site specific release of the therapeutic agent. Disclosed are methods of treating comprise administering a lipid capsule to a target site of a subject in need thereof, wherein the lipid capsule comprises a therapeutic agent; and applying an alternating electric field, at a frequency for a period of time, to the target site of the subject in need thereof, wherein the alternating electric field releases the therapeutic agent from the lipid capsule at the target site of the subject in need thereof. Disclosed are methods of killing a cell comprising administering a lipid capsule to a target site, wherein the lipid capsule comprises a therapeutic agent; and applying an alternating electric field for a period of time, to the target site, wherein the alternating electric field releases the therapeutic agent from the lipid capsule at the target site, wherein the target site comprises a cell, wherein the therapeutic kills the cell.

The application provides a conjugate based on hydroxyl radical ultrasonic response and application, having a structure shown in formula I or a salt thereof; the research is started from a reactive substance such as a hydroxyl radical generated by the cavitation effect of ultrasonic, and a plurality of meta-disubstituted benzyl alcohol ultrasonic response structures are designed and screened. After the conjugate is formed by covalent bond between the structure and a to-be-masked molecule such as a drug or a fluorescent contrast molecule, the active groups of the to-be-masked molecule can be masked, and the activity of the to-be-masked molecule can be inhibited, and a molecule obtained is called a prodrug, the prodrug can be a small molecule, and can also be used for a polymer drug loading system. The prodrug can capture the hydroxyl radical generated by the cavitation effect of ultrasonic under the condition of no ultrasound sensitizer, and release the target molecule by elimination reaction. Through experimental screening, it is found that the meta-benzene diether structure is the best ultrasonic response group.

The present application discloses the pharmaceutical use of a composition for treating atherosclerosis. Specifically, it relates to the use of a composition comprising microbubbles and copper ions in the preparation of a medicament for treating atherosclerosis. The microbubble and copper ion composition disclosed in the present application significantly reduces the plaque area when treating atherosclerosis, but does not cause plaque fragmentation and shedding.

This invention belongs to the field of biomedical technology, specifically relating to a Pt 2+ - Carbon dot@protoporphyrin sonodynamic drug delivery system, its preparation method and application, by loading Pt onto the surface of carbon dots 2+ Modification layer, to obtain Pt 2+ After carbon dots are formed, protoporphyrin is loaded onto them to obtain a carbon dot core with Pt loaded on the carbon dot surface. 2+ Modification layer, in Pt 2+ A sonodynamic drug delivery system with a protoporphyrin-modified layer loaded on the outside of the modified layer can be used in anti-tumor drugs to screen liver cancer cells and normal cells. It has good biocompatibility and significant in vivo sonodynamic anti-tumor effects. It can promote the generation of reactive oxygen species, target and remain in the subcutaneous tumor site in vivo for a long time, increase the mortality rate of cancer cells, and inhibit tumor growth. In a 3D constructed in vitro hepatocellular tumor microenvironment model, this drug delivery system still has superior sonodynamic therapeutic effects.

The invention relates to methods of sonodynamic therapy comprising the co-administration of a microbubble-chemotherapeutic agent complex together with a microbubble-sonosensitiser complex. It further relates to pharmaceutical compositions comprising these complexes and their use in methods of sonodynamic therapy and / or sonodynamic diagnosis. Such methods find particular use in the treatment of cancer, e.g. pancreatic cancer.

The application provides preparation and application of a single near-infrared waveband cationic organic small-molecule material antibacterial agent with photo-thermal and photodynamic effects. A water-soluble molecular structure with a structure shown in formula (IV) or isomers, pharmaceutically acceptable salts, hydrates or solvates, preparation of a pharmaceutical composition and application thereof in antibacterial and / or tumor synergistic phototherapy are provided. The orthogonal structure compound provided by the application can realize intramolecular charge transfer, prolong the triplet state lifetime of the molecule, convert the triplet state into singlet state oxygen in the presence of oxygen, and convert light energy into heat energy, so that photodynamic and photo-thermal combined treatment is realized, the defects of single phototherapy are made up, and the phototherapy effect is enhanced.

Particles comprised of a transition metal oxide and an amphiphilic copolymer, having a predetermined particle size, and uses same for encapsulation of hydrophobic compounds and for sono-responsive therapy, are disclosed. The methods of manufacturing the particles with a predetermined particle size are disclosed.

The application discloses a kind of acoustically powered targeted nanomaterials and its preparation method and application, belong to medical technology field.The nanomaterial includes chemotherapeutic drug, heat-producing sound sensitizer, metal organic framework that the chemotherapeutic drug and the heat-producing sound sensitizer are loaded, liposome membrane that the metal organic framework is coated, tumor marker that is loaded on the surface of the liposome membrane.The nanomaterial enters human body, can target combination tumor cell, through the acoustically powered excitation sound sensitizer in nanomaterial and the release of chemotherapeutic drug (such as paclitaxel) heat production, to simulate the heat chemotherapy process in tumor peritoneal metastasis treatment, combine heat therapy and chemotherapy, obtain a new tumor peritoneal metastasis treatment scheme;The treatment scheme improves chemotherapy effect while reducing the side reaction of patient's whole body, improves the treatment effect of patient, prolongs the life cycle of patient.

An arrangement and a device including the arrangement allow nanoagents that have therapeutic or diagnostic or both therapeutic and diagnostic effects to be vaporized in a specific target area in the human body. The arrangement includes at least one primary magnetic element configured to generate a first magnetic field in a first direction, at least one secondary magnetic element configured to generate a second magnetic field substantially opposite to the first direction, at least one tertiary magnetic element configured to generate a time-varying magnetic field to excite magnetic nanoparticles located in a magnetic field-free region where the opposite first magnetic field and the second magnetic field suppress each other's effects, at least one receiving coil configured to measure the magnetization of magnetic nanoparticles, and at least one first ultrasound transducer configured to apply ultrasound energy by providing acoustic waves onto the nanoagents located in the magnetic field-free region.

This invention discloses a MEC nanoprobe, its preparation method, and its applications. The MEC nanoprobe is composed of Mn... 3+ The sample was prepared using TCPP, Erastin, and CD133mab, with CD133mab coupled to the surface. The preparation method involved adding Mn... 3+ Mn-TCPP-MOF was synthesized by stirring TCPP in an N,N-dimethylformamide solution containing acetic acid; Erastin was then added and stirred at room temperature, followed by centrifugation, washing, and redispersing in deionized water; the amide bonds were then activated via EDC / NHS and coupled to CD133mAb to obtain MEC nanoprobes. The combined application of this MEC nanoprobe with a TGFβ1R inhibitor can block both the classical ferroptosis resistance pathway and CAF-related pathways, achieving dual-channel blockade of ferroptosis resistance in pancreatic cancer. Furthermore, dual-modal imaging enables semi-quantitative in vivo visualization assessment of ferroptosis resistance, demonstrating promising clinical application prospects.

Provided are methods for improving an expression of a nucleic acid construct in a cell or an organ of a subject using sonoporation and optimization of ultrasonic acoustic energy mechanical index.

The invention provides polymeric particles comprising a matrix of a biocompatible polymer and polyethylene imine, said matrix having incorporated therein an anionic or hydrophobic sonosensitiser and, optionally, an immunomodulatory agent and / or an imaging agent. Such particles find use in methods of sonodynamic therapy, in particular in methods of combined sonodynamic therapy and immunotherapy, for example in the treatment of cancer, metastasis or micrometastasis derived from cancer. The invention is particularly suitable for the treatment of deep-sited, hard to treat tumours such as pancreatic cancer.

Disclosed in the present application is a use of a composition in treating atherosclerosis. Specifically, the present application relates to a use of a composition comprising microbubbles and copper ions in treating atherosclerosis.

Systems and methods for producing liposomes, including control liposomes and immunoliposomes targeting breast cancer are provided. Systems and methods for treating breast cancer, using targeted immunoliposomes produced according to various methods are also disclosed herein. For example, trastuzumab-conjugated immunoliposomes may be used to deliver chemotherapeutic agents to breast cancer tissues for the treatment of breast cancer. Systems and methods for actuating liposomes using ultrasound are also disclosed, such as systems and methods for actuating trastuzumab-conjugated liposomes accumulated in breast cancer tissues for the treatment of breast cancer.